Cargando…

Liquid Biopsy in Glioblastoma

SIMPLE SUMMARY: Glioblastoma is the most common and malignant primary brain tumor. Despite intensive research for new treatments, the survival of patients has not significantly improved in recent decades. Currently, glioblastoma is mainly diagnosed by neuroimaging techniques followed by histopatholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ronvaux, Lorian, Riva, Matteo, Coosemans, An, Herzog, Marielle, Rommelaere, Guillaume, Donis, Nathalie, D’Hondt, Lionel, Douxfils, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323318/
https://www.ncbi.nlm.nih.gov/pubmed/35884454
http://dx.doi.org/10.3390/cancers14143394
_version_ 1784756521052143616
author Ronvaux, Lorian
Riva, Matteo
Coosemans, An
Herzog, Marielle
Rommelaere, Guillaume
Donis, Nathalie
D’Hondt, Lionel
Douxfils, Jonathan
author_facet Ronvaux, Lorian
Riva, Matteo
Coosemans, An
Herzog, Marielle
Rommelaere, Guillaume
Donis, Nathalie
D’Hondt, Lionel
Douxfils, Jonathan
author_sort Ronvaux, Lorian
collection PubMed
description SIMPLE SUMMARY: Glioblastoma is the most common and malignant primary brain tumor. Despite intensive research for new treatments, the survival of patients has not significantly improved in recent decades. Currently, glioblastoma is mainly diagnosed by neuroimaging techniques followed by histopathological and molecular analysis of the resected or biopsied tissue. Both imaging and tissue-based methods have, despite their advantages, some important limitations highlighting the necessity for alternative techniques such as liquid biopsy. It appears as an attractive and non-invasive alternative to support the diagnosis and the follow-up of patients with glioblastoma and to identify early recurrence. Liquid biopsy, primarily through blood tests, involves the detection and quantification of tumoral content released by tumors into the biofluids. The aim of the present review is to discuss the biological bases, the advantages, and the disadvantages of the most important circulating biomarkers so far proposed for glioblastoma. ABSTRACT: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.
format Online
Article
Text
id pubmed-9323318
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93233182022-07-27 Liquid Biopsy in Glioblastoma Ronvaux, Lorian Riva, Matteo Coosemans, An Herzog, Marielle Rommelaere, Guillaume Donis, Nathalie D’Hondt, Lionel Douxfils, Jonathan Cancers (Basel) Review SIMPLE SUMMARY: Glioblastoma is the most common and malignant primary brain tumor. Despite intensive research for new treatments, the survival of patients has not significantly improved in recent decades. Currently, glioblastoma is mainly diagnosed by neuroimaging techniques followed by histopathological and molecular analysis of the resected or biopsied tissue. Both imaging and tissue-based methods have, despite their advantages, some important limitations highlighting the necessity for alternative techniques such as liquid biopsy. It appears as an attractive and non-invasive alternative to support the diagnosis and the follow-up of patients with glioblastoma and to identify early recurrence. Liquid biopsy, primarily through blood tests, involves the detection and quantification of tumoral content released by tumors into the biofluids. The aim of the present review is to discuss the biological bases, the advantages, and the disadvantages of the most important circulating biomarkers so far proposed for glioblastoma. ABSTRACT: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed. MDPI 2022-07-13 /pmc/articles/PMC9323318/ /pubmed/35884454 http://dx.doi.org/10.3390/cancers14143394 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ronvaux, Lorian
Riva, Matteo
Coosemans, An
Herzog, Marielle
Rommelaere, Guillaume
Donis, Nathalie
D’Hondt, Lionel
Douxfils, Jonathan
Liquid Biopsy in Glioblastoma
title Liquid Biopsy in Glioblastoma
title_full Liquid Biopsy in Glioblastoma
title_fullStr Liquid Biopsy in Glioblastoma
title_full_unstemmed Liquid Biopsy in Glioblastoma
title_short Liquid Biopsy in Glioblastoma
title_sort liquid biopsy in glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323318/
https://www.ncbi.nlm.nih.gov/pubmed/35884454
http://dx.doi.org/10.3390/cancers14143394
work_keys_str_mv AT ronvauxlorian liquidbiopsyinglioblastoma
AT rivamatteo liquidbiopsyinglioblastoma
AT coosemansan liquidbiopsyinglioblastoma
AT herzogmarielle liquidbiopsyinglioblastoma
AT rommelaereguillaume liquidbiopsyinglioblastoma
AT donisnathalie liquidbiopsyinglioblastoma
AT dhondtlionel liquidbiopsyinglioblastoma
AT douxfilsjonathan liquidbiopsyinglioblastoma